Currently Unavailable
Enter your email to be notified when this product is available.
Dual glucagon/GLP-1 receptor agonist. 10mg lyophilized powder per vial.
All compounds independently tested and verifiedLab results →
Survodutide
What It Is
Survodutide is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim. Unlike tirzepatide (GIP/GLP-1), survodutide pairs glucagon with GLP-1. The glucagon component is specifically designed to attack fatty liver — it forces the liver to burn its fat stores. This makes survodutide particularly interesting for anyone concerned about liver health alongside weight management.
How It Works
Glucagon receptor activation drives hepatic fat oxidation and thermogenesis. GLP-1 receptor activation suppresses appetite and improves insulin sensitivity. The GLP-1 component counterbalances glucagon's blood-sugar-raising effects. The net result: liver fat burns off while appetite stays suppressed.
What The Research Shows
Phase 2 MASLD trials: up to 64% of participants normalized their liver fat — remarkable numbers for fatty liver.
Weight loss of up to 18.7% over 46 weeks.
Improved liver enzymes, triglycerides, and HbA1c across the board.
Phase 3 trials (SYNCHRONIZE program) ongoing for obesity and MASLD.
Sources
Survodutide for the treatment of metabolic-associated steatotic liver disease
Sanyal AJ et al. — N Engl J Med, 2024 · PubMed
Information derived from published preclinical and clinical research. Provided for educational purposes only — not medical advice.
Customer Reviews
- Ryan K.★★★★★
Customer service is top notch and fast delivery!
- Jamie★★★★★
Had my order confirmation instantly, shipping information within hours and product delivered in 2 business days.
- Jessica T.★★★★★
Great communication when a product came back in stock and even got a free bottle of bac water!
- Sanjiv R.★★★★★
Product quality is the best and had it delivered to my office within 72 hours of ordering.